Advertisement Claims and Comparisons under S.I. No. 42 of 2024
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Nigeria is one of the few markets that has written advertising vocabulary into legal definitions. Regulation 51 of the interpretation section sets explicit thresholds:
- “Fast” = the claimed effect is observed within 30 minutes;
- “Immediate”/“Instant” = the claimed effect is observed within 10 seconds.
Three companion rules apply: Regulation 41 (claims must be substantiated; absolute statements prohibited), Regulation 42 (false or misleading statements, incomplete truths, vague superiority claims, and “magic”/“miracle” style wording prohibited), and Regulation 43 (factual comparison is permitted but identifiable brands must not be named, and charts must be accurate and show sources).
2. Legal basis
| Instrument | Reference number | Date | Provisions |
|---|---|---|---|
| NAFDAC Medical Devices and Related Products (Registration, Labelling and Advertisement) Regulations, 2024 | S.I. No. 42 of 2024 | 16 October 2024 | Regulation 41 (claims), Regulation 42 (restrictions), Regulation 43 (misleading comparisons), Regulation 35 (no claim of endorsement by national or international bodies), Regulation 51 (interpretation: Fast = 30 minutes; Immediate/Instant = 10 seconds; Top Parity) |
| NAFDAC Guidelines for Registration of Medical Devices Including In Vitro Diagnostics (IVDs) and Related Products | VBM-R&RA-GDL-001-01 | Effective 10 April 2025 | §11.3 (registration is not an advertisement permit) |
| NAFDAC Guidelines for Registration of Medical Devices (Imported and Locally Manufactured) in Nigeria | R&R-GDL-008-02 | Effective 3 May 2024 | §12.3 (no automatic advertisement permit) |
3. Expert insights
Insight 1: quantifying sensory words is the hardest-edged design in Nigerian advertising regulation.
Most markets rely on general language such as no exaggeration, leaving the judgment to discretion. Nigeria instead gives two numbers — 30 minutes and 10 seconds — turning words like fast and immediate from adjectives into measurable claims. The practical consequence: if you use these words, you must produce performance studies that can prove the stated time threshold. A claim that cannot be tied to a study measuring the effect within the defined window is simply indefensible before the authority, however common the wording may be in other markets.
Insight 2: the four restricted categories in Regulation 41 carry different evidentiary burdens.
Regulation 41 addresses in turn: statements such as safest and guaranteed effectiveness; superlatives must have empirical support; best-selling must not imply product superiority; and fast/immediate/instant/rapid must be supported by performance studies. The strictness differs across the four: the first two are effectively prohibitions, while the latter two can be used once the evidence is supplied. Marketing teams therefore need to know which column a proposed claim falls into before copy is drafted, not after the permit application has been filed and returned.
Insight 3: Regulation 42 prohibits the incomplete truth — which is broader than falsehood.
The scope of Regulation 42 covers false or misleading statements, incomplete truths, vague claims of superiority, and “magic” or “miracle” style wording. An incomplete truth means that presenting only the advantages while hiding material limitations is itself a violation — for example, stressing detection rates without mentioning the false positive rate. The same analysis catches selective quotations of study results, or performance figures quoted without the conditions under which they were obtained.
Insight 4: Regulation 43 gives comparative advertising two workable rules.
Rule one: a factual comparison is allowed, but identifiable brand names must not be indicated. Rule two: where charts or graphs are used for comparison, they must be accurate and must indicate the source. Taken together, the clauses mark out one clearly workable path: speak with data, name no brand, cite the source.
Insight 5: Regulation 35 is the clause foreign companies most easily trip over.
Regulation 35 provides that advertisements must not claim endorsement by a national or international body. Chinese companies often cite a CE certificate or WHO prequalification as a selling point — in Nigeria, if such wording is read as a claim of institutional endorsement, it is a violation. The correct approach is to state facts (for example, that a CE certificate has been obtained) without any implication of endorsement, and to obtain the advertisement permit in advance. The distinction is one of framing: the certificate may be described, but it must not be presented as the institution vouching for the product.
4. Practical recommendations
- Build a banned-word list for advertising covering fast/immediate/instant/rapid, safest, guaranteed, best-selling, magic and miracle, and run machine screening on all copy.
- Whenever a quantified time word is used, prepare the supporting performance study in advance and submit it with the advertisement permit application.
- In comparative advertising, use factual data only, name no brand, and cite chart sources (Regulation 43).
- Rewrite endorsement-style statements into neutral factual statements (Regulation 35).
- Review bilingual materials in parallel, so restricted wording is not introduced during translation.
- Obtain the advertisement permit before any publication, and never substitute the registration certificate (§11.3/§12.3; see article 30).
5. Verification checklist
- □ Advertising copy has passed banned-word screening (Regulations 41 and 42).
- □ Fast/immediate/instant/rapid claims are supported by performance studies (Regulation 51: 30 minutes / 10 seconds).
- □ Comparative advertising names no identifiable brand, and charts are accurate with sources cited (Regulation 43).
- □ No implied claim of endorsement by an institution (Regulation 35).
- □ Bilingual materials have both been reviewed.
- □ The advertisement permit has been obtained and is not substituted by the registration certificate (§11.3/§12.3).
Regulatory information verified as of 29 October 2026. All content cited in this document has been checked against the official NAFDAC regulation text (S.I. No. 42 of 2024, Regulations 35, 41, 42, 43 and 51) and the two guidelines (VBM-R&RA-GDL-001-01 §11.3, effective 10 April 2025; R&R-GDL-008-02 §12.3, effective 3 May 2024); the thresholds Fast = 30 minutes and Immediate/Instant = 10 seconds are stated verbatim in the interpretation of Regulation 51.
- Local Nigeria resources: GRZAN can coordinate locally licensed import entities and authorized representative resources, covering NAPAMS online submission, dossier screening clearance interfacing, import permits, sample delivery and laboratory analysis support.
- Service capability: classification determination, registration pathway selection, technical documentation (IMDRF ToC) drafting, CMFS and notarization/legalization, GMP and foreign inspection preparation, advertisement permits, vigilance and PMS reporting, change management and renewal.
- Contact: info@grzanglobal.com; website www.grzan.cn.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us